IMEXHS LIMITED (IME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IME - IMEXHS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -43.42
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.55

18 Apr
2024

-0.010

OPEN

$0.55

-1.79%

HIGH

$0.55

16,375

LOW

$0.55

TARGET
$1.50 172.7% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IDX . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
IME: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx N/A 1.1 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 49.1 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-10.0
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx19.7 M
Book Value Per Share xxxxxxxxxxxxxxx37.5
Net Operating Cash Flow xxxxxxxxxxxxxxx2.6 M
Net Profit Margin xxxxxxxxxxxxxxx-21.31 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-26.30 %
Return on Invested Capital xxxxxxxxxxxxxxx-25.69 %
Return on Assets xxxxxxxxxxxxxxx-19.21 %
Return on Equity xxxxxxxxxxxxxxx-26.30 %
Return on Total Capital xxxxxxxxxxxxxxx-14.34 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx1.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx6 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx2 M
Price To Book Value xxxxxxxxxxxxxxx1.79

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx2.2 M
Capex % of Sales xxxxxxxxxxxxxxx11.16 %
Cost of Goods Sold xxxxxxxxxxxxxxx16 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx6 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

01/03/2024

1

Speculative Buy

$1.50

172.73%

Revenue for ImExHS in FY23 was in line with Morgans forecast, but earnings (EBITDA) fell short of the broker's estimate as the services division created a margin drag across the business due to higher software development costs.

The key forward metric, according to the broker, is annual recurring revenue (ARR), which rose by 27% on the previous corresponding period to $25m (Radiology services $14.5m, Software $10.5m).

Management guided to FY24 revenue growth of 22-37%, underlying earnings in the range of $1.5-3.5m and further operating cash flow (OCF) improvement over FY24.

Speculative Buy. The target falls to $1.50 from $1.80.

FORECAST
Morgans forecasts a full year FY24 dividend of 0.00 cents and EPS of 1.10 cents.
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of 11.60 cents.
Access Stockbroker Research History >

IME STOCK CHART

FNArena News on IME

1
FNArena Corporate Results Monitor – 01-03-2024

Mar 01 2024 - Australia
2
FNArena Corporate Results Monitor – 01-09-2023

Sep 01 2023 - Australia
3
FNArena Corporate Results Monitor – 01-03-2023

Mar 01 2023 - Australia
4
FNArena Corporate Results Monitor – 31-08-2022

Aug 31 2022 - Australia
5
FNArena Corporate Results Monitor – 02-03-2022

Mar 02 2022 - Australia

Latest Medical Equipment & Devices News

1
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
2
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
3
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View
4
Dr Boreham’s Crucible: Artrya

Feb 15 2024 - Small Caps
5
ResMed Recovery Turns Into Hollywood Script

Jan 31 2024 - Australia
6
ResMed Makes A Comeback

Jan 29 2024 - Australia
7
ResMed: The Recovery Has Begun

Jan 23 2024 - Technicals
8
Dr Boreham’s Crucible: Pro Medicus

Oct 23 2023 - Australia
9
Dr Boreham’s Crucible: Cyclopharm

Oct 09 2023 - Small Caps
10
Dr Boreham’s Crucible: Painchek

Sep 11 2023 - Small Caps